Therefore, it is considered that different mechanisms are underlying the response to chemotherapy and TKIs in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutation, but which subpopulation will respond better to chemotherapy or TKIs is still unknown. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.